Drug profile

The FDA adverse-event record for Florfenicol, Terbinafine, Betamethasone Acetate Gel

15 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Florfenicol, Terbinafine, Betamethasone Acetate Gel. See the species affected, top reactions, and outcomes below.

15
adverse-event reports
0.0%
death-coded share
Dog
most-reported species
3
Loss of hearing - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
15
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Florfenicol, Terbinafine, Betamethasone Acetate Gel

Administration Routes

Auricular (Otic)

Species Affected

Dog 14
Cat 1

Most Affected Breeds

Shih Tzu 2
Chihuahua 2
Retriever - Golden 2
Domestic Shorthair 1
Sheepdog (unspecified) 1
Terrier - Boston 1
Bloodhound 1
Dog (other) 1
Terrier - Jack Russell 1
Shepherd Dog - German 1

Most Reported Reactions

Loss of hearing 3
Deafness 2
Vomiting 2
Restlessness 2
Lethargy (see also Central nervous system depression in 'Neurological') 2
Application site inflammation 2
Vestibular disorder NOS 1
Inappetence 1
Swelling around eye 1
Hyphaemia 1
Third eyelid extrusion 1
Thrombocytopenia 1

Outcome Breakdown

Recovered/Normal
8 (53.3%)
Outcome Unknown
5 (33.3%)
Recovered with Sequela
1 (6.7%)
Ongoing
1 (6.7%)

Florfenicol, Terbinafine, Betamethasone Acetate Gel Adverse Event Insights

15 reports name Florfenicol, Terbinafine, Betamethasone Acetate Gel; 0 recorded a death outcome (0.0% of reported events, not a population-level mortality rate). Active ingredient: Florfenicol, Terbinafine, Betamethasone Acetate Gel. Administration route: Auricular (Otic).

By species: Dog (14 reports), Cat (1 reports). By breed: Shih Tzu (2), Chihuahua (2), Retriever - Golden (2).

Leading clinical signs: Loss of hearing (3), Deafness (2), Vomiting (2), Restlessness (2). Outcome, 15 coded reports: Recovered/Normal leads at 53.3%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.